Source: http://www.scribd.com/doc/233550674/Merck-Sharp-Dohme-v-Hospira
Timestamp: 2014-12-18 14:12:51
Document Index: 372749741

Matched Legal Cases: ['§ 1331', '§ 1391', '§ 1400', '§355', '§355', '§355', '§ 271']

P. 1Merck Sharp & Dohme v. HospiraMerck Sharp & Dohme v. HospiraRatings: (0)|Views: 24
|Likes: 0Published by PriorSmartOfficial Complaint for Patent Infringement in Civil Action No. 1:14-cv-00915-UNA: Merck Sharp & Dohme Corp. v. Hospira Inc. Filed in U.S. District Court for the District of Delaware, no judge yet assigned. See http://news.priorsmart.com/-laGx for more info.Official Complaint for Patent Infringement in Civil Action No. 1:14-cv-00915-UNA: Merck Sharp & Dohme Corp. v. Hospira Inc. Filed in U.S. District Court for the District of Delaware, no judge yet assigned. See http://news.priorsmart.com/-laGx for more info.More info:Categories:Types, Business/Law, Court FilingsPublished by: PriorSmart on Jul 12, 2014Copyright:Public DomainAvailability:Read on Scribd mobile: iPhone, iPad and Android.download as PDF, TXT or read online from ScribdFlag for inappropriate content|Add to collectionSee moreSee lesshttps://www.scribd.com/doc/233550674/Merck-Sharp-Dohme-v-Hospira07/27/2014pdftextoriginal IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MERCK SHARP & DOHME CORP., Plaintiff, v. HOSPIRA, INC., Defendant. ))))))))) C.A. No. ___________________ COMPLAINT FOR PATENT INFRINGEMENT Plaintiff Merck Sharp & Dohme Corp., by way of Complaint against Hospira, Inc., alleges as follows: THE PARTIES 1.
Merck Sharp & Dohme Corp. (“Merck”) is a corporation organized and existing under the laws of the state of New Jersey, having a principal place of business at One Merck Drive, Whitehouse Station, New Jersey 08889. Merck is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health. 2.
On information and belief, Hospira, Inc. is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business at 275 North Field Drive, Lake Forest, Illinois 60045-2510. 3.
On information and belief, Hospira is in the business of developing and manufacturing generic pharmaceutical products, which are copies of products invented and developed by innovator pharmaceutical companies. 2 JURISDICTION AND VENUE 4.
This action arises under the patent laws of the United States. This Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331 and 1338(a). 5.
Hospira is subject to personal jurisdiction in this District because it is a corporation organized and existing under the laws of the State of Delaware. 6.
Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391(b) and (c), and/or 28 U.S.C. § 1400(b). MERCK’S NDA AND ASSERTED PATENT 7.
Merck filed New Drug Application (“NDA”) No. 021337, pursuant to which the U.S. Food and Drug Administration (“FDA”) granted approval for lyophilized powder in vials containing 1.046 g ertapenem sodium equivalent to 1g ertapenem for intravenous infusion or for intramuscular injection. The ertapenem described in NDA No. 021337 is an antibacterial product approved for use in adults and pediatric patients for the treatment of complicated intra-abdominal infections; complicated skin and skin structure infections; community acquired pneumonia; complicated urinary tract infections; and acute pelvic infections. The ertapenem of NDA No. 021337 is also approved in adults for the prophylaxis of surgical site infection following elective colorectal surgery. Ertapenem is sold by Merck under the trade name Invanz
Merck is the owner of U.S. Patent No. 5,952,323 (the “‘323 patent”) which is attached as Exhibit A. The ‘323 patent discloses and claims stabilized forms of the ertapenem compound, and methods of stabilizing the ertapenem compound. 9.
Pursuant to 21 U.S.C. §355(b)(1), Merck has submitted information concerning the ‘323 patent to the FDA in connection with its NDA No. 021337, identifying it as 3 a patent “with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner engaged in the manufacture, use, or sale of the drug.” The ‘323 patent has been listed in the FDA publication entitled “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the “Orange Book”) as covering Invanz. HOSPIRA’S ANDA AND NOTICE LETTER 10.
By letter (“Hospira Notice Letter”) dated May 29, 2014, and received by Merck on May 30, 2014, Hospira gave notice that it had submitted Abbreviated New Drug Application (“ANDA”) No. 206480 to the FDA under 21 U.S.C. §355(j) seeking approval to manufacture, use and sell ertapenem for injection 1g (the “Hospira Generic Product”), prior to the expiration of the ‘323 patent. 11.
The Hospira Notice Letter informed Merck that Hospira’s ANDA contained a “Paragraph IV Certification” that the ‘323 patent is invalid. 12.
This action is being filed within 45 days of Merck’s receipt of Hospira’s Notice Letter. COUNT I – INFRINGEMENT OF ‘323 PATENT 13.
Merck realleges, as if fully set forth herein, the averments contained in paragraphs 1-12. 14.
Hospira submitted ANDA No. 206480 to the FDA under 21 U.S.C. §355(j) to obtain approval to engage in the commercial manufacture, use, or sale of the Hospira Generic Product prior to the expiration of the ‘323 patent. By submitting this application, Hospira has committed an act of infringement under 35 U.S.C. § 271(e)(2)(A). Activity (1)FiltersAdd to collectionReview Add NoteLikeShowingAllMost RecentReviewsAll NotesLikesYou've already reviewed this. Edit your review.Rating 0/5Post notePost reviewPost replyPost note and like1 hundred readsLoad more